Gimeracil

Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) [1][2].

Product Specifications

CAS Number

[103766-25-2]

Product Name Alternative

Gimestat

UNSPSC

12352005

Hazard Statement

H302

Target

Dihydropyrimidine Dehydrogenase (DPD) ; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gimeracil.html

Concentration

10mM

Purity

99.72

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C=C(O)C(Cl)=CN1

Molecular Formula

C5H4ClNO2

Molecular Weight

145.54

Precautions

H302

References & Citations

[1]Masaru Takagi, et al. Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. Radiother Oncol. 2010 Aug;96 (2) :259-66.|[2]Koh-Ichi Sakata, et al. Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. Cancer Sci. 2011 Sep;102 (9) :1712-6.|[3]Masakazu Fukushima, et al. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep. 2010 Nov;24 (5) :1307-13.